Jubilant HollisterStier Announces COVID-19 Vaccine Candidate Manufacturing Agreement With Novavax
Source: Jubilant HollisterStier
![vaccine vaccine](https://vertassets.blob.core.windows.net/image/3b251516/3b251516-7363-49d0-8468-e573d09c7369/375_250-vaccine.jpg)
Jubilant HollisterStier LLC, a wholly owned subsidiary of Jubilant Pharma Limited, announced that it has entered into a non-exclusive manufacturing agreement with Novavax, a biotechnology company developing next-generation vaccines for serious infectious diseases, to provide fill-finish manufacturing services for the production of COVID-19 vaccine candidate NVX-CoV2373.
Under the terms of the agreement, Jubilant HollisterStier’s Spokane, Washington facility has begun production activities of NVX-CoV2373 final drug product intended for commercial distribution in the United States.
Source: Jubilant HollisterStier
Jubilant HollisterStier
This website uses cookies to ensure you get the best experience on our website. Learn more